Recruitment is underway for a clinical trial in Brazil to determine if CBD treatment can improve depressive and anxiety symptoms in individuals with bipolar disease.
Improvement in functioning and inflammatory biomarkers will also be assessed.
The study is expected to be completed by February 2020.
Approximately 100 study participants will receive 600mg/day of CBD (or placebo) for a period of 12 weeks.
The double-blind, randomized and placebo controlled study will be led by Márcia Kauer-Sant’Anna, MD, PhD at Hospital de Clinicas de Porto Alegre, in Rio Grande do Sul.
The University of Sao Paulo and Federal University of Rio Grande do Sul are research collaborators.